CASP1 and metabolic dysfunction-associated steatohepatitis: Also, selective pharmacological inhibition of NLRP3 lowered aminotransferases levels and reduced hepatic inflammation in the in vivo NASH models43,44 and this effect was associated with a significant reduction in CASP1 activation44.